GT BIOPHARMA INC

GTBPNASDAQ

🏆 #3686 by market capEarnings Aug 12US Equity

$990.00▲ $68.21 (+6.89%)

Simulated price

1h—

24h▲ 6.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$14M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

36.5%

Healthy

💵FCF Margin

17.5%

Healthy

⚖️P/S Ratio

225.6x

Expensive

Otter Score

Fair

No chart data available for GTBP.

Trading Snapshot

Day Range: $979.15 – $1,006.63
52-Week Range: $0.26 – $1.89
Volume: $2.52B
Avg Volume: $1.98B
Shares Outstanding: 44.3M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $61,467
Last Q Revenue: $17,195
P/E Ratio: —
P/S Ratio: 225.6x
EPS (TTM): $-10.65
Dividend Yield: —

Why Investors Own GTBP

✓High-growth profile — revenue up +2.5% YoY with expanding US Equity exposure.
✓Healthy economics — 53% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$61,467▼ −1.9% YoY

Gross Margin (TTM)

53.3%▲ +0.9% YoY

Operating Income (TTM)

$10,572▼ −1.9% YoY

Free Cash Flow (TTM)

$9,282▼ −1.9% YoY

About GT BIOPHARMA INC

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

🦦